EPICYPHER
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$80.0k | Grant | ||
* | N/A | - | |
* | N/A | $3.3m | Early VC |
Total Funding | CAD4.6m |
Recent News about EPICYPHER
EditEpiCypher is a pioneering company in the field of epigenetics and chromatin biology research, providing cutting-edge tools and services to scientists. The company specializes in high-performance ChIP antibody validation through its SNAP ChIP technology, which ensures superior specificity and enrichment in ChIP experiments. EpiCypher also offers advanced mass spectrometry solutions, such as the Nuc MS technology, which allows for the detection of histone post-translational modifications (PTMs) and variants within intact mononucleosomes. This innovative approach simplifies the analysis of histone codes and their cooperative functions, addressing a significant challenge in the field.
EpiCypher collaborates with leading researchers and institutions to deliver these innovative solutions, catering primarily to academic and pharmaceutical research labs focused on oncology, gene expression, and genetic networks. The company's business model revolves around the sale of specialized research tools and services, generating revenue through product sales and service contracts.
Keywords: epigenetics, chromatin biology, ChIP antibody validation, mass spectrometry, histone PTMs, nucleosomes, oncology research, gene expression, genetic networks, research tools.